SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

ALT5 Sigma Corp
Date: Aug. 6, 2025 · CIK: 0000862861 · Accession: 0000000000-25-008280

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289176

Date
August 6, 2025
Author
Division of
Form
UPLOAD
Company
ALT5 Sigma Corp

Letter

Re: ALT5 Sigma Corporation Registration Statement on Form S-3 Filed August 1, 2025 File No. 333-289176 Dear Peter Tassiopoulos:

August 6, 2025

Peter Tassiopoulos Chief Executive Officer ALT5 Sigma Corporation 325 E. Warm Springs Road, Suite 102 Las Vegas, NV 89119

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Dickerson at 202-551-8013 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Peter Campitiello, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 6, 2025

Peter Tassiopoulos
Chief Executive Officer
ALT5 Sigma Corporation
325 E. Warm Springs Road, Suite 102
Las Vegas, NV 89119

 Re: ALT5 Sigma Corporation
 Registration Statement on Form S-3
 Filed August 1, 2025
 File No. 333-289176
Dear Peter Tassiopoulos:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jessica Dickerson at 202-551-8013 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Peter Campitiello, Esq.
</TEXT>
</DOCUMENT>